Pfizer’s JAK inhibitors improve hair regrowth in patients with alopecia areata

Pfizer’s Janus kinase (JAK) inhibitors, including PF-06651600 and PF-06700841, have achieved primary efficacy endpoint of improving hair regrowth in patients with moderate to severe alopecia areata (AA) in phase 2a study.